

Patient Name: MRS SUJATA MARAKWAD

: 32 Yrs/Female

Ref. Dr. : MEDIWHEEL

Age/Gender

SCD24/3025

: 30/03/2024



HAEMATOLOGY REPORT

Report Date

Test Description	Result	Unit	Biological Reference Range		
COMPLETE BLOOD COUNT					
Total WBC Count	6800	cell/cu.mm	4000 - 11000		
Haemoglobin	10.9	g%	11 - 16		
Platelet Count	361000	/cumm	150000 - 450000		
RBC Count	3.76	/Mill/ul	3.50 - 5.50		
RBC INDICES					
Mean Corp Volume MCV	90.4	fL	80 - 97		
Mean Corp Hb MCH	29.0	pg	26 - 32		
Mean Corp Hb Conc MCHC	32.1	gm/dL	31.0 - 36.0		
Hematocrit HCT	34.0	%	36.0 - 48.0		
DIFFERENTIAL LEUCOCYTE CO	UNT				
Neutrophils	58	%	40 - 75		
Lymphocytes	34	%	20 - 45		
Monocytes	05	· %	02 - 10		
Eosinophils	02	%	01 - 06		
Basophils NOTE:	01	%	00 - 01		

^{1.} As per the recommendation of International council for Standardization in Hematology, the differential leukocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of blood.

BLOOD GROUP AND RH FACTOR

Blood Group 'A'

Rh Factor POSITIVE(+VE)

Dr.S R. SARDA
M.D. Reg. No.#5468
SARDA CENTER FOR DIABFTES & SELF CARE
4, Vyankateshneger, Julina Road, Aurangabad
Phone No.2333851, 2334858

^{2.} Test conducted on EDTA whole blood.



Patient Name: MRS SUJATA MARAKWAD

: 32 Yrs/Female Report Date

17

Ref. Dr. : MEDIWHEEL

mm/hr

: 30/03/2024



ESR

Male: 0-8 mm at 1 Hr. Female: 0-20 mm at 1 Hr.

Method: Automated Westergren

INTERPRETATION:

Age/Gender

1. It indicates presence and intensity of an inflammatory process, never diagnostic of a specific disease. Changes are more significant than a single abnormal test.

2. It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, bacterial endocarditis, acute rheumatic fever, rheumatoid arthritis, SLE, Hodgkins disease, temporal arteritis, polymyalgia rheumatica.

3. It is also increased in pregnancy, multiple myeloma, menstruation, and hypothyroidism.

Dr.S R. SARDA
M.D. Reg. No. #5468

SARDA CENTER FOR DIABFTES & SELF CARE
4, Vyankateshnegar, Jaina Road, Aurangabad
Phone No.2333851, 2334858



Patient Name: MRS SUJATA MARAKWAD

: 32 Yrs/Female

Ref. Dr. : MEDIWHEEL

SCD24/3025

Report Date : 30/03/2024



HBA1C/GLYCOCYLATED

HbA1c Glycosilated Haemoglobin

5.7

%

Method: HPLC, NGSP certified

Age/Gender

Estimated Average Glucose:

117

mg/dL

As per American Diabetes Association (ADA)				
Reference Group	HbA1c in %			
Non diabetic adults >=18 years	<5.7			
At risk (Prediabetes)	5.7 - 6.4			
Diagnosing Diabetes	>= 6.5			
Therapeutic goals for glycemic control	Age > 19 years Goal of therapy: < 7.0 Action suggested: > 8.0 Age < 19 years Goal of therapy: <7.5			

ADA criteria for correlation			
HbA1c(%)	Mean Plasma Glucose (mg/dL)		
6	126		
7	154		
8	183		
9	212		
10	240		
11	269		
12	298		

Note:1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled .

2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.

Comments:HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

Dr.S.R. SARDA
M.D. Reg. No.55462
SARDA CENTER FOR DIABFTES & SELF CARE
4, Vyankateshneger, Jaima Road, Aurangabad
Phone No.2333851, 2334858



Patient Name: MRS SUJATA MARAKWAD

Age/Gender

Ref. Dr.

SCD24/3025 : 32 Yrs/Female

: MEDIWHEEL

: 30/03/2024 Report Date



BIOCHEMISTRY REPORT

			
Test Description	Result	Unit	Biological Reference Range
LIPID PROFILE			
Cholesterol-Total Method: CHOD/PAP	132	mg/dL	< 200 : Desirable 200-239 : Borderline risk > 240 : High risk
Triglycerides level Method: Lipase / Glycerol Kinase)	90	mg/dL	< 150 : Normal 150–199 : Borderline-High 200–499 : High > 500 : Very High
HDL Cholesterol Method: CHOD/PAP	41	mg/dL	< 40 : Low 40 - 60 : Optimal > 60 : Desirable
LDL Cholesterol Method: Homogeneous enzymatic end point assay	73.00	mg/dL	< 100 : Normal 100 - 129 : Desirable 130 – 159 : Borderline-High 160 – 189 : High > 190 : Very High
VLDL Cholesterol Method: Calculation	18.00	mg/dL	7 - 40
CHOL/HDL RATIO Method: Calculation	3.22	Ratio	3.5 - 5.0
LDL/HDL RATIO Method: Calculation	1.78	Ratio	0 - 3.5

Wethod. Odicalation				
Interpretation				
Lipid profile can measure the amount of	f Total cholesterol's and triglycerides in blood:			
Test	Comment			
Total cholesterol:	measures all the cholesterol in all the lipoprotein particles			
High-density lipoprotein cholesterol (HDL-C):	measures the cholesterol in HDL particles; often called "good cholesterol" because HDL-C takes up excess cholesterol and carries it to the liver for removal.			
Low-density lipoprotein cholesterol (LDL-C):	measures the cholesterol in LDL particles; often called "bad cholesterol" because it deposits excess cholesterol in walls of blood vessels, which can contribute to atherosclerosis			
Triglycerides:	measures all the triglycerides in all the lipoprotein particles; most is in the very low-density lipoproteins (VLDL).			





Patient Name: MRS SUJATA MARAKWAD

: 32 Yrs/Female

Ref. Dr. : MEDIWHEEL

Age/Gender

SCD24/3025

: 30/03/2024



BIOCHEMISTRY REPORT

Report Date

Test Description	Result	Unit	Biological Reference Range
BLOOD SUGAR FASTING & PP (BSI	F & PP)		
BLOOD SUGAR FASTING	74	mg/dl	
Method: Hexokinase			
BLOOD SUGAR POST PRANDIAL	122	mg/dl	
Method: Hexokinase			
ADA 2019 Guidelines for diagnosis of Di	abetes Mellitus		

Fasting Plasma Glucose > 126 mg/dl Postprandial Blood Glucose > 200 mg/dl Random Blood Glucose > 200 mg/dl HbA1c Level > 6.5%

M.D. Reg. No.85468

SARDA CENTER FOR DIABFTES & SELF CARE
4, Vyankateshnegar, Julina Road, Aurangabad
Phone No.2333851, 2334858



Patient Name: MRS SUJATA MARAKWAD

Age/Gender : 32 Yrs/Female

Ref. Dr. : MEDIWHEEL

SCD24/3025

Report Date

: 30/03/2024



BIOCHEMISTRY REPORT

Test Description	Result	Unit	Biological Reference Range
UREA Method: UV	23	mg/dl	10 - 45
Serum Creatinine Method: Modified Jaffe's	0.74	mg/dL	0.60 - 1.40

...ourour moumou ourro

Dr.S.R. SARDA
M.D. Reg. No.#5468
SARDA CENTER FOR DIABFTES & SELF CARE
4, Vyankateshneger, Julina Road, Aurangabad
Phone No.2333851, 2334858



Patient Name: MRS SUJATA MARAKWAD

SCD24/3025

Age/Gender Ref. Dr.

: 32 Yrs/Female : MEDIWHEEL

Report Date

: 30/03/2024



LIVER FUNCTION TEST (LFT)

TOTAL BILIRUBIN	0.72	mg/dl	0.2 - 1.0
Method: Serum, Jendrassik Grof			
DIRECT BILIRUBIN	0.21	mg/dL	0.0 - 0.3
Method: Serum, Diazotization			
INDIRECT BILIRUBIN	0.51	mg/dl	0.3 - 1.0
Method: Serum, Calculated			
SGPT (ALT)	21	U/L	15 - 40
Method: Serum, UV with P5P, IFCC 37 degree			
SGOT (AST)	26	U/L	15 - 40
Method: Serum, UV with P5P, IFCC 37 degree			
ALKALINE PHOSPHATASE	80	U/L	30 - 120
Method: DGKC			
TOTAL PROTEIN	7.6	g/dl	6.0 - 8.0
Method: Serum, Biuret, reagent blank end point			
SERUM ALBUMIN	4.1	g/dl	3.2 - 4.6
Method: Serum, Bromocresol green			
SERUM GLOBULIN	3.50	g/dl	1.8 - 3.6
Method: Serum, Calculated			
A/G RATIO	1.17		1.2 - 2.2
Method: Serum, Calculated			
Gamma Glutamyl Transferase-Serum	24	IU/L	12 - 43
Method: Kinetic			

NOTE:

In known cases of Chronic Liver disease due to Viral Hepatitis B & C, Alcoholic liver disease or Non alcoholic fatty liver disease, Enhanced liver fibrosis (ELF) test may be used to evaluate liver fibrosis.





Patient Name: MRS SUJATA MARAKWAD

: 32 Yrs/Female : MEDIWHEEL SCD24/3025

Report Date : 30/03/2024



IMMUNOASSAY REPORT

Test Description	Result	Unit	Biological Reference Range		
Thyroid Function Test (TFT)					
Т3	105.02	ng/dl	80-253 : 1 Yr-10 Yr,		
		· ·	76-199 : 11 Yr-15 Yr,		
			69-201 :16 Yr-18 Yr,		
			87-173 : > 18 years,		
T4	8.35	ng/dl	5.9-21.5 :10-31 Days,		
		· ·	5.9-21.5 :0-1 Month,		
			6.4-13.9 :2-12 Months,		
			6.09-12.23 :>1 Yr		
TSH(Serum)	1.33	ng/dl	0.52-16.0 :1 Day - 30 Days		
		· ·	0.55-7.10 :1 Mon-5 Years		
			0.37-6.00 :6 Yrs-18 Years		
			0.38-5.33 :18 Yrs-88 Years		
			0.50-8.90 :88 Years		

Method: ECLIA

Age/Gender

Ref. Dr.

Clinical features of thyroid disease				
Hypothyroidism	Hyperthyroidism	Grave's disease		
Lethargy	Tachycardia	Exophthalmos/proptosis		
Weight gain	Palpitations (atrial fibrillation)	Chemosis		
Cold intolerance	Hyperactivity	Diffuse symmetrical goitre		
Constipation	Weight loss with increased appetite	Pretibial myxoedema (rare)		
Hair loss	Heat intolerance	Other autoimmune conditions		
Dry skin	Sweating			
Depression	Diarrhoea			
Bradycardia	Fine tremor			
Memory impairment	Hyper-reflexia			
Menorrhagia	Goitre			
	Palmar erythema			
	Onycholysis			
	Muscle weakness and wasting			
	Oligomenorrhea/amenorrhoea			





Patient Name: MRS SUJATA MARAKWAD

Age/Gender : 32 Yrs/Female

Ref. Dr. : MEDIWHEEL

SCD24/3025

Report Date : 30/03/2024



URINE EXAMINATION REPORT

Result	Unit	Biological Reference Range
	-	
Pale Yellow		Pale Yellow
Clear		Clear
Acidic		
Absent		
1.010		
Absent		
NIL		Absent
Absent		
Absent		Absent
Absent		Absent
14		
Not seen	/hpf	Nil
1-2/hpf	/hpf	2-3/hpf
NIL	/hpf	1-2/hpf
Absent		Absent
NOT FOUND		Not Seen
	Pale Yellow Clear Acidic Absent 1.010 Absent NIL Absent Absent Absent Not seen 1-2/hpf NIL Absent	Pale Yellow Clear Acidic Absent 1.010 Absent NIL Absent Absent Absent Not seen /hpf 1-2/hpf /hpf NIL /hpf Absent

**** End of the report. ****

Absent

Dr.S. R. SARDA
M.D. Reg. No. \$5468
SARDA CENTER FOR DIABFTES & SELF CARE
4, Vyankateshneger, Jairva Road, Aurangabad
Phone No.2333851, 2334858

Absent

Amorphous Deposit